Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Date of Report: January 27, 2026
Event: Regulation FD Disclosure regarding the issuance of a shareholder letter providing updates on prior and future operations.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of a shareholder communication rather than a financial statement.
Material Changes
No material financial changes or comparative period data are disclosed within the text of this Form 8-K. The document references an attached press release (Exhibit 99.1) for operational updates.
Guidance, Outlook, and Risks
- Management Commentary: The Company issued a shareholder letter updating stakeholders on prior and future operations.
- Legal Status of Information: The information in Item 7.01 and Exhibit 99.1 is furnished and not deemed "filed" under Section 18 of the Exchange Act. It is not subject to liabilities under Section 18 or Sections 11 and 12(a)(2) of the Securities Act.
- Incorporation by Reference: This information shall not be incorporated by reference into other Company filings unless expressly set forth by specific reference.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific details on the shareholder letter and operational updates.
- Verify the Company's current cash position and runway, as this 8-K does not contain financial data.
- Monitor subsequent filings (10-Q or 10-K) for formal financial reporting and any incorporation of the shareholder letter's content.